Correlation Engine 2.0
Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

Pyriproxyfen is used in Brazil to combat epidemics of Dengue Fever, Chikungunya Fever, and Zika virus. This study assessed the effects of pyriproxyfen on reproductive performance, embryo-fetal development, head measurements, and DNA integrity in a preclinical model. Thirty pregnant mice were divided into three groups (n = 10): control (drinking water-0.1 ml/10 g (body weight-b.w., gavage) and treated with pyriproxyfen 0.0002 mg/kg and 0.0021 mg/kg (b.w., gavage) during the gestational period. Analysis of biometric, reproductive performance and embryo-fetal development parameters related to control presented no significant differences, suggesting no maternal or embryo-fetal toxicity. Head measurements showed no differences except an increase in anterior/posterior measurement and glabella/external occipital protuberance. Analysis of DNA integrity showed an increase in micronucleus only at 72 h for the lowest dose group. Thus, we infer that pyriproxyfen is not related to the occurrence of microcephaly, nor does it alter reproductive performance, embryo-fetal development or DNA integrity.

Citation

Juliana Miron Vani, Laynna de Carvalho Schweich-Adami, Sarah Alves Auharek, Andréia Conceição Millan Brochado Antoniolli-Silva, Rodrigo Juliano Oliveira. Pyriproxyfen does not cause microcephaly or malformations in a preclinical mammalian model. Environmental science and pollution research international. 2021 Jan;28(4):4585-4593

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 32948939

View Full Text